SINGAPORE, March 16, 2023 (GLOBE NEWSWIRE) — Novotech, a leading biotechnology CRO focused on Asia-Pacific, has released a new report on the current status of clinical trials for multi-specific monoclonal antibodies (Mabs) at globally, including analysis of growth hubs across Asia-Pacific, Europe and the United States.
The new report Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape maybe downloaded here.
The report concluded that between 2018 and 2022, there had been more than 1,000 global trials of multi-species Mabs, with the Asia-Pacific region having been involved in around 40% of the trials, the United States around 30% and Europe around 22%.
Asia-Pacific was the fastest growing region in multi-species Mabs trials with a 5-year CAGR of over 37%, representing nearly twice and three times the growth rates of the United States and from Europe respectively.
The majority of multi-specific Mabs drugs (85%-90%) in clinical trials currently being conducted in these three major regions target oncology indications. Most are early phase trials (phase I) and mid-phase trials (phase II), while more than 15 of them are in phase III.
In addition, the Asia-Pacific region had the highest share of oncology trials, at 90%, and the percentage of oncology for the United States and Europe was 84% and 82% respectively. .
The report also looked at the reasons why the Asia-Pacific region has become a hub for Mabs, including the benefits for patient recruitment.
According to the report, over the 5-year period from 2018 to 2022, due to patient access, the Asia-Pacific region had a 30% shorter median trial duration than the United States. and a median trial duration more than 40% shorter than in Europe. Similarly, the Asia-Pacific region recruited 38% faster than the United States and almost three times faster than Europe.
In the Asia-Pacific region, China plays a leading role in the multi-species antibody testing industry.
The report noted that a growing number of biopharmaceutical companies are gaining access to proprietary platforms to gain a foothold in the Chinese Mabs market. In addition, the government’s ongoing initiatives to encourage the development of new treatments by implementing new laws and reforming current regulations are making the Chinese immunotherapy industry more attractive.
Novotech has decades of experience in biotech drug development, established relationships with sites and investigators, access to large patient populations, and a problem-solving, ownership and trust-driven project management approach. flexibility.
Through constant investment in training and cutting-edge technology, we can provide a complete and exceptional biotech CRO solution.
Novotech recently received major CRO awards, including the Asia-Pacific Biotech CRO of the Year award from Frost & Sullivan, it was ranked among the Top 10 CROs in the world, was a finalist in the prestigious Scrip Awards and just received the Gene & Cell Therapy Excellence Award.
In the Asia-Pacific region, Novotech has more than 50 cutting-edge partnership agreements with leading research institutions that offer exclusive benefits to sponsors.
Novotech, which has global regulatory advisory and CRO operations, announced from JPMorgan this year that it had acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in several strategically important regions. across the continent.
The acquisition is part of Novotech’s global expansion program. EastHORN was established in 2004 and has over 250 employees.
With the acquisition of EastHORN, biotechnology clients can access Novotech’s unique and unrivaled suite of early to late phase CRO services in Europe and the United States, with a particular focus on the Asia-Pacific region where the company has earned a reputation for providing high quality, accelerated clinical trials.
About Novotech Novotech-CRO.com
Novotech is the leading biotechnology CRO focused on Asia-Pacific with global execution capabilities. Novotech is a clinical CRO equipped with laboratories, Phase I facilities, drug development consulting services and FDA regulatory expertise. She has gained experience in more than 5,000 clinical projects, including clinical trials from Phase I to Phase IV and bioequivalence studies. Novotech is positioned to serve biotechnology customers conducting clinical trials in Asia-Pacific, the United States and Europe. Novotech has more than 3,000 employees worldwide and 33 offices across the United States, Europe and the Asia-Pacific region.
For more information, visit
